RxDoctor Payments Data

Samantha Bouchie, MD

Internal Medicine · Carmel, INNPI 1003131871

Payments from drug & device makers

$712in general payments, 2019–2025

Across 34 payments — averaging $20.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$203
  • AbbVie$158
  • Boston Scientific$51
  • AstraZeneca$48
  • Amgen$42
  • Astellas Pharma US Inc$37
  • plus $173 from 9 others

What the payments were for

  • Food & beverage$712100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$712 in reported general payments places this provider in the 70th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$28,718
Medicare patients
155
Services billed
273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban60$51,016
JardianceEmpagliflozin31$46,751
MounjaroTirzepatide38$45,323
MyrbetriqMirabegron31$30,251
OzempicSemaglutide13$23,052
XareltoRivaroxaban16$18,036
TrulicityDulaglutide12$11,863
Breo ElliptaFluticasone/Vilanterol11$5,760
SynthroidLevothyroxine Sodium54$3,796
Levothyroxine Sodium238$2,589
Duloxetine Hcl63$2,377
Rosuvastatin Calcium188$2,069
Nebivolol Hcl21$1,804
Pantoprazole Sodium125$1,639
Atorvastatin Calcium211$1,614

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$17$57,18650 claims
PfizerEliquis$17$51,01660 claims
Astellas Pharma US IncMyrbetriq$37$30,25131 claims
Novo NordiskOzempic$203$23,05213 claims
AbbVieSynthroid$158$3,79654 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Carmel

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →